S&P 500   3,304.01 (+0.29%)
DOW   26,806.03 (+0.53%)
QQQ   269.45 (+0.03%)
AAPL   437.46 (+0.39%)
MSFT   211.91 (-2.14%)
FB   248.97 (-1.19%)
GOOGL   1,470.22 (-0.85%)
AMZN   3,124.35 (+0.40%)
NVDA   446.83 (+1.46%)
CGC   19.34 (+1.47%)
BABA   261.73 (+1.47%)
TSLA   1,474.73 (-0.69%)
MU   51.14 (+1.49%)
GE   6.14 (+0.49%)
AMD   85.12 (+9.59%)
T   29.98 (+1.22%)
F   6.85 (+2.39%)
ACB   10.75 (+3.17%)
GILD   70.71 (-1.42%)
NFLX   508.07 (+1.90%)
DIS   117.50 (+0.99%)
BAC   24.96 (-0.12%)
BA   165.06 (+1.72%)
S&P 500   3,304.01 (+0.29%)
DOW   26,806.03 (+0.53%)
QQQ   269.45 (+0.03%)
AAPL   437.46 (+0.39%)
MSFT   211.91 (-2.14%)
FB   248.97 (-1.19%)
GOOGL   1,470.22 (-0.85%)
AMZN   3,124.35 (+0.40%)
NVDA   446.83 (+1.46%)
CGC   19.34 (+1.47%)
BABA   261.73 (+1.47%)
TSLA   1,474.73 (-0.69%)
MU   51.14 (+1.49%)
GE   6.14 (+0.49%)
AMD   85.12 (+9.59%)
T   29.98 (+1.22%)
F   6.85 (+2.39%)
ACB   10.75 (+3.17%)
GILD   70.71 (-1.42%)
NFLX   508.07 (+1.90%)
DIS   117.50 (+0.99%)
BAC   24.96 (-0.12%)
BA   165.06 (+1.72%)
S&P 500   3,304.01 (+0.29%)
DOW   26,806.03 (+0.53%)
QQQ   269.45 (+0.03%)
AAPL   437.46 (+0.39%)
MSFT   211.91 (-2.14%)
FB   248.97 (-1.19%)
GOOGL   1,470.22 (-0.85%)
AMZN   3,124.35 (+0.40%)
NVDA   446.83 (+1.46%)
CGC   19.34 (+1.47%)
BABA   261.73 (+1.47%)
TSLA   1,474.73 (-0.69%)
MU   51.14 (+1.49%)
GE   6.14 (+0.49%)
AMD   85.12 (+9.59%)
T   29.98 (+1.22%)
F   6.85 (+2.39%)
ACB   10.75 (+3.17%)
GILD   70.71 (-1.42%)
NFLX   508.07 (+1.90%)
DIS   117.50 (+0.99%)
BAC   24.96 (-0.12%)
BA   165.06 (+1.72%)
S&P 500   3,304.01 (+0.29%)
DOW   26,806.03 (+0.53%)
QQQ   269.45 (+0.03%)
AAPL   437.46 (+0.39%)
MSFT   211.91 (-2.14%)
FB   248.97 (-1.19%)
GOOGL   1,470.22 (-0.85%)
AMZN   3,124.35 (+0.40%)
NVDA   446.83 (+1.46%)
CGC   19.34 (+1.47%)
BABA   261.73 (+1.47%)
TSLA   1,474.73 (-0.69%)
MU   51.14 (+1.49%)
GE   6.14 (+0.49%)
AMD   85.12 (+9.59%)
T   29.98 (+1.22%)
F   6.85 (+2.39%)
ACB   10.75 (+3.17%)
GILD   70.71 (-1.42%)
NFLX   508.07 (+1.90%)
DIS   117.50 (+0.99%)
BAC   24.96 (-0.12%)
BA   165.06 (+1.72%)
Log in

LON:CLINClinigen Group Share Price, Forecast & News

GBX 719
+13.50 (+1.91 %)
(As of 07/14/2020)
Add
Compare
Today's Range
687.50
Now: GBX 719
721.50
50-Day Range
705.50
MA: GBX 770.92
827
52-Week Range
7.47
Now: GBX 719
1,039
Volume233,370 shs
Average Volume432,646 shs
Market Capitalization£955.54 million
P/E Ratio69.13
Dividend Yield0.92%
BetaN/A
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Trial Segment supplies and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More
Clinigen Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars


Industry, Sector and Symbol

Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1283-495010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£491.70 million
Cash FlowGBX 28.89 per share
Book ValueGBX 332.40 per share

Profitability

Miscellaneous

Employees849
Market Cap£955.54 million
Next Earnings Date9/17/2020 (Estimated)
OptionableNot Optionable
GBX 719
+13.50 (+1.91 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLIN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Clinigen Group (LON:CLIN) Frequently Asked Questions

How has Clinigen Group's stock been impacted by COVID-19 (Coronavirus)?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CLIN shares have increased by 9.4% and is now trading at GBX 719.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Clinigen Group?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Clinigen Group
.

When is Clinigen Group's next earnings date?

Clinigen Group is scheduled to release its next quarterly earnings announcement on Thursday, September 17th 2020.
View our earnings forecast for Clinigen Group
.

How were Clinigen Group's earnings last quarter?

Clinigen Group PLC (LON:CLIN) issued its quarterly earnings results on Tuesday, February, 25th. The company reported $30.80 EPS for the quarter, missing analysts' consensus estimates of $31.00 by $0.20.
View Clinigen Group's earnings history
.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group declared a dividend on Tuesday, February 25th. Stockholders of record on Thursday, March 19th will be given a dividend of GBX 2.15 per share on Friday, April 17th. This represents a yield of 0.29%. The ex-dividend date of this dividend is Thursday, March 19th. The official announcement can be accessed at this link.
View Clinigen Group's dividend history
.

What price target have analysts set for CLIN?

4 brokerages have issued twelve-month target prices for Clinigen Group's stock. Their forecasts range from GBX 820 to GBX 1,300. On average, they expect Clinigen Group's share price to reach GBX 1,112.50 in the next twelve months. This suggests a possible upside of 54.7% from the stock's current price.
View analysts' price targets for Clinigen Group
.

Has Clinigen Group been receiving favorable news coverage?

News articles about CLIN stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Clinigen Group earned a news impact score of -3.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future.
View the latest news about Clinigen Group
.

Who are some of Clinigen Group's key competitors?

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Application (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP).

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 51)
  • Mr. Nicholas Keher, CFO & Director
  • Ms. Debra Ainge, Chief Operating Officer
  • Matt Parrish, Head of Investor Relations
  • Mr. David Bryant, Director of Corp. Devel.

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 719.

How big of a company is Clinigen Group?

Clinigen Group has a market capitalization of £955.54 million and generates £491.70 million in revenue each year. Clinigen Group employs 849 workers across the globe.

What is Clinigen Group's official website?

The official website for Clinigen Group is www.clinigengroup.com.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.